Navigation Links
Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Date:11/4/2007

Study Supports Dose-dependent Activity of Antidote Component

ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Regado Biosciences today presented data from a randomized, double-blind, placebo-controlled Phase Ic study of the Company's REG1 Anticoagulation System. REG1 is a two-component system comprised of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The study results support RB007's ability to reverse the anticoagulant effect of RB006 either completely or partially, depending on the level of dosing of RB007. Consistent with previously reported Phase I results, these data were presented by the Duke Clinical Research Institute at the American Heart Association's 2007 Scientific Sessions, currently being held in Orlando, Florida.

Clinical researchers from the Duke Clinical Research Institute and Regado randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The study showed repeated doses of RB006 achieved highly reproducible increases in activated partial thromboplastin time (aPTT), a well-accepted surrogate marker of the blood's ability to clot. Subsequently, repeat doses of RB007 reversed the aPTT levels dose-dependently and reproducibly. There were no major bleeding episodes or other serious adverse events reported in this study.

"I am encouraged by RB007's activity to date in reversing or neutralizing the anticoagulant effect of RB006, either completely or partially, as needed. The potential to modulate coagulation quickly based on the patient's condition represents an advance in anticoagulation therapy that could advance clinical care," said Ro
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 ... economics and outcomes research also   to   be ... SHPG ), the global specialty biopharmaceutical company, ... poster presentations at the American Psychiatric Association (APA) 166th ... May 18-22. The data being presented represent Shire,s ongoing ...
(Date:5/17/2013)... , Puerto Rico , May 17, 2013 ... and western Puerto Rico , Caribbean Imaging ... Center has improved its radiation therapy capabilities with the acquisition ... Puerto Rico . Versa HD offers clinicians the ... of tumors throughout the body, while also enabling treatment of ...
(Date:5/17/2013)... Genetics, Inc. (NASDAQ: ATOS ), The Breast Health ... Chief Financial Officer & General Counsel, will present at the ... 2013, in New York City at ... is scheduled to begin at 3:30 p.m. EDT and will ... go to www.atossagenetics.com . For more information ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... a Case Management Conference was recently convened for hundreds ... federal multidistrict litigation now underway in U.S. District Court, ... on the Court’s website on May 14th, the Conference ... It was also reported during the Conference that Defendants ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease ... gums and increase the chance of a healthier smile. ... Procedure (LANAP) not only removes diseased gum tissue in patients, ... bone for dental implants. , LANAP uses a ... can also help stimulate the healthy tissue as well as ...
(Date:5/19/2013)... Yeast infections are common in both men and ... the human body. A new yeast infection treatment product has ... unique method of application to help eliminate over growth of ... to men and women searching for a natural process of ... through food and is stored in the intestines. In small ...
(Date:5/19/2013)... 19, 2013 Passages Malibu, the leading ... has announced this week the launch of a “Sobriety, ... social media channels. “We are always looking for ... and to get feedback regarding sobriety, what’s working for ... co-founder of the Passages Addiction Treatment Centers ...
(Date:5/19/2013)... May 19, 2013 The AMTC team will ... the Columbus Georgia Convention & Trade Center on June 1st. ... attend. AMTC auditions are free of charge. , Actors, Models ... for hundreds of successful artists and grads like Caitlin Kinney ... European Tombolini , Chris Young - on his Liquid Neon ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2
... venom that the snails inject to immobilize their prey ... strokes, central nervous system disorders and other ills. ,The ... equivalent of a compound in the venom of the ... tropical saltwater. ,The snail-venom research involved 111 patients ...
... to lower tar cigarettes in hopes of continuing with ... consequences of higher tar cigarettes.// ,Non-filter cigarettes make up ... States and United Kingdom. A new study shows the ... who smoke medium-tar cigarettes, low-tar cigarettes, or very-low-tar cigarettes. ...
... to eating infected beef was first reported in the United ... for the degenerative, fatal brain disorder.// ,Charlene is the ... form of mad cow disease, according to the Centers for ... are sure Charlene caught the disease while living in Britain.Charlene ...
... in intensive care units following a major surgery, and ... of about 50 percent and according to researchers it ... seriously ill patients. // ,A recently discovered ... from failing after injury, according to new research.For the ...
... dementia in people with Down syndrome with those seen ... issue of Neurology.,// ,Studies indicate 50 percent ... will eventually develop signs of dementia, and autopsies show ... the brain tangles and plaques commonly associated with Alzheimer's ...
... death, heart attack and repeat procedures .,A recent study ... drug-coated stents on patients.// ,The study included ... who were treated with drug-eluting stents. An additional 450 ... stents. ,Results of the one-year study show ...
Cached Medicine News:Health News:The Human Mad Cow Case 2Health News:Hope for Patients With Kidney Failure 2Health News:Dementia and Down Syndrome 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: